Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Novo Nordisk briefly becomes Europe's No1 as investors binge on weight-loss stocks

Published 01/09/2023, 13:05
Updated 01/09/2023, 13:40
© Reuters.  Novo Nordisk briefly becomes Europe's No1 as investors binge on weight-loss stocks

Proactive Investors - Novo Nordisk (CSE:NOVOb) became Europe’s largest company for a short time today as investors continued to pile into the Danish drugmaker following the recent trial of fat-busting drug Wegovy.

Shares in Novo have jumped 17% since the trial showed that not only can Wegovy trim the waistline but cuts the risk of heart attack or stroke by a fifth.

At the open this morning, Novo Nordisk had a market capitalisation of $421 billion, just edging out French-listed luxury brands group LVMH (EPA:LVMH) off the top spot.

LVMH had previously been on top since February 2021 when it took over from Nestle.

The French giant subsequently regained its crown, but with demand for fat-reducing drugs soaring, especially in the US, experts suggest it might struggle to hold off the rising Danish group for long.

Barclays (LON:BARC) forecasts weight loss drugs to become a US$100 billion market within 10 years, up from US$6 billion currently, with Novo Nordisk and US group Eli Lilly (NYSE:LLY) leading the way.

Eli Lilly is expected to get US approval for a weight loss label for existing treatment Mounjaro later this year.

In June, it also stunned the medical profession with results from a trial for a new weight loss drug, retatrutide

"Novo closing in on LVMH as Europe's biggest market cap stock is a reflection of Novo's recent product success while LVMH's recent trends have been more mixed," Marcel Stotzel, co-portfolio manager of Fidelity European Fund and Fidelity European Trust, told Reuters.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Wegovy currently costs $1,300 a month in the United States.

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.